A Method Of Assessing Protein Modification Status And Identifying Biomarkers Linked To Cell Signaling Pathways
The present invention provides methods of assessing protein modification status and identifying biomarkers linked to cell signaling pathways. The invention provides a method of creating a dataset of modification sites, comprising grouping modification sites on modified peptides from a first sample which has been treated with a first modulator of a protein modifying enzyme and modification sites on modified peptides from a second sample which has been treated with a second modulator of the same protein modifying enzyme into a single group, according to the effect of said first and second modulators of said protein modifying enzyme on said modification sites, wherein said first and second modulators of said protein modifying enzyme are different. The invention further provides a method of preparing a database, methods of treatment and methods of diagnosis.
1 . A method of creating a dataset of modification sites, comprising grouping modification sites on modified peptides from a first sample which has been treated with a first modulator of a protein modifying enzyme and modification sites on modified peptides from a second sample which has been treated with a second modulator of the same protein modifying enzyme into a single group, according to the effect of said first and second modulators of said protein modifying enzyme on said modification sites, wherein said first and second modulators of said protein modifying enzyme are different.
2 . The method according to claim 1 , wherein said modification sites are selected from the group consisting of phosphorylation sites, acetylation sites, glycosylation sites, methylation sites and lipidation sites.
3 . The method according to claim 1 , wherein said first sample and said second sample is or includes a cell from a cancer cell line.
4 . The method according to claim 1 , wherein said protein modifying enzyme is selected from the group consisting of a protein kinase, protein phosphatase, protein glycosyltransferase, protein acetyltransferase, protein methyltransferase and protein palmitoyltransferase.
5 . The method according to claim 4 , wherein said protein modifying enzyme is a protein kinase.
6 . The method according to claim 1 , wherein said modulator of a protein modifying enzyme is a small molecule, RNAi, therapeutic peptide, or antibody.
7 . The method according to claim 1 , wherein said modulator of a protein modifying enzyme is an inhibitor of a protein modifying enzyme.
8 . The method according to claim 7 , wherein said inhibitor of a protein modifying enzyme is a kinase inhibitor.
9 . The method according to claim 8 , wherein said kinase inhibitor is an inhibitor of a kinase selected from the group consisting of Akt, CAMK2, EGFR, ERK, MEK, mTOR, p70S6K, PI3K, PKC, and ROCK.
10 . The method according to claim 1 , wherein said effect of said first and second modulators of said protein modifying enzyme on said modification site is a reduction or increase in abundance of said modification site compared to a control sample.
11 . A method of preparing a database, comprising creating a dataset of modification sites according to claim 1 , and compiling said dataset into a database.
12 . The method according to claim 11 , wherein said database further comprises information on the identities of proteins containing the modification sites, the type of modification, the type of sample in which the modification site is present and/or the modulator that increases or decreases the modification at the modification site.
13 . A method for diagnosing a disease comprising:
(a) creating a test dataset of modification sites by:
i) treating one or more test samples from a subject with one or more modulators of a protein modifying enzyme,
ii) identifying and/or quantifying modification sites on modified peptides in the one or more test samples,
iii) grouping modification sites on modified peptides from the one or more test samples into a single group, thereby creating the test dataset of modification sites, and
iv) optionally compiling the test dataset into a test database,
(b) comparing the test dataset with a dataset of modification sites created according to the method of claim 1 ,
(c) finding a significant difference between the test dataset or test database and the control dataset or control database, and
(d) diagnosing that the subject has the disease if a significant difference between the dataset or database is found in step (c).
14 . The method of claim 13 , wherein the disease is cancer.
15 . A method of identifying one or more biomarkers for the activity of a protein modifying enzyme comprising creating a dataset of modification sites according to the method of claim 1 , wherein the modification sites in the single group are identified as the one or more biomarkers for the activity of a protein modifying enzyme.
16 . A method of determining that a test substance is a modulator of a protein modifying enzyme comprising treating a test sample with the test substance, identifying and/or quantifying modification sites on modified peptides in the test sample, creating a test dataset of modification sites from the modification sites identified and/or quantified in the test sample, further comprising:
(a) comparing the test dataset with a dataset of modification sites created according to the method of claim 1 .
17 . A method for diagnosing a disease comprising:
(a) creating a test dataset of modification sites by:
i) treating one or more test samples from a subject with one or more modulators of a protein modifying enzyme,
ii) identifying and/or quantifying modification sites on modified peptides in the one or more test samples,
iii) grouping modification sites on modified peptides from the one or more test samples into a single group, thereby creating the test dataset of modification sites, and
iv) optionally compiling the test dataset into a test database,
(b) comparing the test database a database prepared according to claim 11 ,
(c) finding a significant difference between the test dataset or test database and the control dataset or control database, and
(d) diagnosing that the subject has the disease if a significant difference between the dataset or database is found in step (c).
18 . The method of claim 17 , wherein the disease is cancer.
19 . A method of identifying one or more biomarkers for the activity of a protein modifying enzyme comprising preparing a database according to claim 11 , wherein the modification sites in the single group are identified as the one or more biomarkers for the activity of a protein modifying enzyme.
20 . A method of determining that a test substance is a modulator of a protein modifying enzyme comprising treating a test sample with the test substance, identifying and/or quantifying modification sites on modified peptides in the test sample, creating a test dataset of modification sites from the modification sites identified and/or quantified in the test sample, further comprising:
(a) compiling said test dataset into a test database and comparing the test database with a database prepared according to claim 11 .